Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Cold Spring Harb Perspect Med. 2012 Mar;2(3):a006395. doi: 10.1101/cshperspect.a006395.

    Symptomatic and nonamyloid/tau based pharmacologic treatment for Alzheimer disease.

    Source

    University of California, San Diego, California 92093, USA. paisen@ucsd.edu

    Abstract

    In this work we consider marketed drugs for Alzheimer disease (AD) including acetylcholinesterase inhibitors (AChE-Is) and antiglutamatergic treatment involving the N-methyl-d-aspartate (NMDA) receptor. We discuss medications and substances available for use as cognitive enhancers that are not approved for AD or cognitive impairment, and other neurotransmitter-related therapies in development or currently being researched. We also review putative therapies that aim to slow disease progression by mechanisms not directly related to amyloid or tau.

    PMID:
    22393531
    [PubMed - in process]
    PMCID:
    PMC3282492
    Free PMC Article

    Images from this publication.See all images (1)Free text

    Figure 1.

      Supplemental Content

      Icon for HighWire Icon for PubMed Central

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk